RBN013209

Overview

RBN013209 is an orally active small molecule inhibitor of CD38 with an IC 50 of 0.01 to 0.1 μM for human CD38 . RBN013209 prevents the conversion of extracellular NAD + to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > CD38 | Products > Signaling Pathways > LAG-3 | Products > Signaling Pathways > Tim3 | Products > Signaling Pathways > PD-1/PD-L1

Product Information

• Catalog No.: HY-144987
• CAS No.: 2597933-17-8
• Molecular Formula: C19H24N6O3
• Molecular Weight: 384.43
• Purity: 98.63%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution
• Availability: In-stock

Source

Original product source